First author | Year | Country | Sample number (rivaroxaban/aspirin) | Average age (years) (rivaroxaban/aspirin) | Type of surgery | Intervention (rivaroxaban/aspirin) | Follow-up | Endpoints |
---|---|---|---|---|---|---|---|---|
Jiang [10] | 2014 | China | 60/60 | 63.8 ± 6.7/65.1 ± 7.5 | TKA | 10 mg once daily, 14 days/100 mg once daily, 14 days | 42 days | VTE |
Zou [11] | 2014 | China | 102/110 | 63.50/62.70 | TKA | 10 mg once daily, 14 days/100 mg once daily, 14 days | 28 days | VTE, nonmajor bleeding |
Colleoni [12] | 2018 | Brazil | 18/14 | 67.11 ± 7.65/71.21 ± 6.35 | TKA | 10 mg once daily, 14 days/300 mg once daily, 14 days | 90 days | VTE, all-cause mortality |
Anderson (a) [4] | 2018 | Canada | 902/902 | 60.90 ± 11.00/61.30 ± 11.10 | THA | 10 mg once daily, 30 days/81 mg once daily, 30 days | 90 days | VTE, major bleeding, nonmajor bleeding, all-cause mortality |
Anderson (b) [4] | 2018 | Canada | 815/805 | 64.70 ± 8.40/64.60 ± 8.70 | TKA | 10 mg once daily, 9 days/81 mg once daily, 9 days | 90 days | VTE, major bleeding, nonmajor bleeding, all-cause mortality |
Lindquist [13] | 2018 | USA | 440/360 | 65.4/65.8 | THA or TKA | 10 mg once daily, THA: 35 days, TKA: 12 days/325 mg twice daily, THA: 35 days, TKA: 12 days | 30 days | major bleeding, nonmajor bleeding |
Yuenyongviwat [14] | 2019 | Thailand | 76/79 | 71.41 ± 6.17/70.08 ± 5.22 | TKA | 10 mg once daily, 14 days/100 mg once daily, 14 days | 42 days | VTE, major bleeding, nonmajor bleeding |
Huang [15] | 2019 | China | 192/198 | 67.8 ± 16.9/69.4 ± 17.4 | HFS | 10 mg once daily, 14 days/100 mg once daily, 16 days | 90 days | VTE, major bleeding, nonmajor bleeding |